XRCC1 and Patent ductus arteriosus: While the significance of XRCC1 elevations in PDAs not known, we reasoned that pharmacological inhibition of BER in PDA, instead of segregating PDA patients based on XRCC1 expression, would be the most practical strategy to enhance tumor specificity and efficacy of ß-lap (ARQ761).